Immune cell therapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new treatment using specially engineered immune cells (CAR macrophages) that are designed to find and attack a protein called c-MET on pancreatic cancer cells. It may help people whose cancer has not responded to previous treatments or who could not tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic cancer that cannot be removed by surgery or has spread to the abdomen or pelvis.
- You have tried at least one prior treatment for your cancer, or could not tolerate that treatment.
- Your cancer cells show a certain level of the c-MET protein (a marker on cancer cells).
- You are generally in good health, with adequate organ function (like kidney, liver, and blood counts).
- You have an expected survival of at least 4 months.
- You are not pregnant or breastfeeding, and agree to use birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.
This trial tests a new type of immunotherapy called CAR-NK cells (CL-NK-001) for patients with advanced pancreatic cancer that has a specific marker (eGR1). The goal is to see if these specially grown natural killer cells can attack the cancer after standard treatments have stopped working.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests an experimental cell therapy using immune cells called iNKT cells, which are designed to attack pancreatic cancer. It may be an option for people who have already tried standard treatments and are looking for something new.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.